File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: COPP chemotherapy for elderly patients with intermediate and high grade non-Hodgkin's lymphoma

TitleCOPP chemotherapy for elderly patients with intermediate and high grade non-Hodgkin's lymphoma
Authors
Issue Date1993
PublisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/3182
Citation
Hematological Oncology, 1993, v. 11 n. 1, p. 43-50 How to Cite?
AbstractOne hundred and forty-one consecutive patients above and 231 below the age of 60 years with previously untreated intermediate or high grade non-Hodgkin's lymphoma were included in this study. Patients above the age of 60 years were treated with the COPP chemotherapy regimen. The young patients, at or below the age of 60, received a doxorubicin-containing regimen (119 had CHOP, 65 had BACOP and 47 had m-BACOD). For stage I patients, the clinical results were similar but for stage II, III or IV disease, those receiving COPP had significantly worse CR rate and survival than those who had a doxorubicin-containing regimen. Multivariate analysis on patients receiving the COPP chemotherapy revealed that the independent prognostic variables significantly determing CR rate and survival included clinical stage (p = 0.04) and serum lactate dehydrogenase level (p = 0.001). Myelosuppression was the major toxicity following COPP chemotherapy in this group of patients. There were 10 (7 per cent) treatment-related deaths. Compared to the reported results using doxorubicin-containing regimens to treat elderly patients with aggressive NHL in the literature, the more aggressive treatment does not appear to improve significantly the clinical outcome of this group of patients and seems to produce treatment results very much similar to COPP. However, accurate comparison is difficult because of the variation in the patient characteristics. Further prospective controlled randomized trials will be necessary to determine the optimal therapy for these patients.
Persistent Identifierhttp://hdl.handle.net/10722/161979
ISSN
2015 Impact Factor: 3.494
2015 SCImago Journal Rankings: 0.767
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLiang, Ren_US
dc.contributor.authorTodd, Den_US
dc.contributor.authorChan, TKen_US
dc.contributor.authorChiu, Een_US
dc.contributor.authorLie, Aen_US
dc.contributor.authorHo, Fen_US
dc.date.accessioned2012-09-05T05:16:26Z-
dc.date.available2012-09-05T05:16:26Z-
dc.date.issued1993en_US
dc.identifier.citationHematological Oncology, 1993, v. 11 n. 1, p. 43-50en_US
dc.identifier.issn0278-0232en_US
dc.identifier.urihttp://hdl.handle.net/10722/161979-
dc.description.abstractOne hundred and forty-one consecutive patients above and 231 below the age of 60 years with previously untreated intermediate or high grade non-Hodgkin's lymphoma were included in this study. Patients above the age of 60 years were treated with the COPP chemotherapy regimen. The young patients, at or below the age of 60, received a doxorubicin-containing regimen (119 had CHOP, 65 had BACOP and 47 had m-BACOD). For stage I patients, the clinical results were similar but for stage II, III or IV disease, those receiving COPP had significantly worse CR rate and survival than those who had a doxorubicin-containing regimen. Multivariate analysis on patients receiving the COPP chemotherapy revealed that the independent prognostic variables significantly determing CR rate and survival included clinical stage (p = 0.04) and serum lactate dehydrogenase level (p = 0.001). Myelosuppression was the major toxicity following COPP chemotherapy in this group of patients. There were 10 (7 per cent) treatment-related deaths. Compared to the reported results using doxorubicin-containing regimens to treat elderly patients with aggressive NHL in the literature, the more aggressive treatment does not appear to improve significantly the clinical outcome of this group of patients and seems to produce treatment results very much similar to COPP. However, accurate comparison is difficult because of the variation in the patient characteristics. Further prospective controlled randomized trials will be necessary to determine the optimal therapy for these patients.en_US
dc.languageengen_US
dc.publisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/3182en_US
dc.relation.ispartofHematological Oncologyen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAged, 80 And Overen_US
dc.subject.meshAging - Physiologyen_US
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - Adverse Effects - Therapeutic Useen_US
dc.subject.meshBleomycin - Administration & Dosageen_US
dc.subject.meshCyclophosphamide - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshDoxorubicin - Administration & Dosageen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshLymphoma, Non-Hodgkin - Drug Therapyen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshNeoplasm Stagingen_US
dc.subject.meshPrednisone - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshProcarbazine - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshVincristine - Administration & Dosage - Adverse Effectsen_US
dc.titleCOPP chemotherapy for elderly patients with intermediate and high grade non-Hodgkin's lymphomaen_US
dc.typeArticleen_US
dc.identifier.emailLiang, R:rliang@hku.hken_US
dc.identifier.authorityLiang, R=rp00345en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1002/hon.2900110106-
dc.identifier.pmid7686880-
dc.identifier.scopuseid_2-s2.0-0027277021en_US
dc.identifier.volume11en_US
dc.identifier.issue1en_US
dc.identifier.spage43en_US
dc.identifier.epage50en_US
dc.identifier.isiWOS:A1993LK72200005-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridLiang, R=26643224900en_US
dc.identifier.scopusauthoridTodd, D=7201388182en_US
dc.identifier.scopusauthoridChan, TK=7402687762en_US
dc.identifier.scopusauthoridChiu, E=24827833600en_US
dc.identifier.scopusauthoridLie, A=24284842400en_US
dc.identifier.scopusauthoridHo, F=7103408147en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats